Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment
Status:
Completed
Trial end date:
2021-02-16
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blinded, and placebo controlled phase III clinical trial
which aims to investigate the superiority of hydroxychloroquine, favipiravir or
hydroxychloroquine + favipiravir treatment, initiated especially in the early period in the
treatment of COVID-19, over the patients being followed up with placebo in adults aged 18~59
Years.